No products in the cart.
Sale
Sitagliptin and Metformin Hydrochloride Extended 100mg low price supplier
Original price was: $6.00.$3.00Current price is: $3.00.
Formulated for laboratory research use, Sitagliptin and Metformin Hydrochloride Extended-Release Tablets combine a DPP-4 inhibitor and biguanide. Manufactured by Qilu Pharmaceutical (Hainan) Co., Ltd., approved under H20253718.
Description
Sitagliptin and Metformin Hydrochloride Extended-Release Tablets are a fixed-dose combination widely used in experimental studies involving type 2 diabetes mellitus (T2DM). This dual-action formulation features a DPP-4 inhibitor (sitagliptin) and a biguanide (metformin)—making it highly relevant for glucose metabolism, insulin resistance, and incretin pathway research.
Developed by Qilu Pharmaceutical (Hainan) Co., Ltd., this compound is approved under H20253718 and is intended exclusively for in vitro or in vivo laboratory research.
Not for human or animal consumption. For experimental use only.
Product Parameters
| Attribute | Details |
|---|---|
| Product Name | Sitagliptin and Metformin Hydrochloride ER Tablets |
| Chinese Name | 西格列汀盐酸二甲双胍缓释片 |
| CAS (Sitagliptin) | 486460-32-6 |
| CAS (Metformin) | 657-24-9 |
| Molecular Formula | C16H15F6N5O·C4H11N5·HCl |
| Strength | [Specification to be confirmed – typically 50mg/500mg or 100mg/1000mg] |
| Dosage Form | Extended-Release Tablets |
| Approval Number | H20253718 (NMPA China) |
| Product Code | 86905847001237 |
| Manufacturer | Qilu Pharmaceutical (Hainan) Co., Ltd. |
| Storage | Store below 25°C; avoid humidity |
| Packaging | Boxed tablets (exact unit count TBD) |
| Use Restriction | Laboratory use only |
Mechanism & Research Applications
This combination tablet works via two complementary mechanisms:
Sitagliptin inhibits DPP-4, increasing incretin hormones (GLP-1, GIP), enhancing insulin release and reducing glucagon in hyperglycemia.
Metformin reduces hepatic glucose production and improves peripheral glucose uptake.
Research applications include:
Glucose metabolism and insulin resistance studies
Evaluation of incretin pathway regulation
Investigations in combination therapy vs monotherapy efficacy
Experimental models of T2DM progression and treatment resistance
Preclinical pharmacokinetic and bioavailability analysis
Observed Effects in Research
Studies using this combination have reported:
Enhanced insulin sensitivity
Reduced postprandial glucose spikes
Improved -cell preservation
Attenuated hepatic gluconeogenesis
Synergistic glycemic control vs monotherapies Suitable for diabetes research
Safety & Handling
Use: For in vitro and in vivo research only
Protective Measures: Wear gloves, lab coat, and eye protection
Storage: Keep sealed, dry, and below 25°C
Disposal: As per lab chemical protocols
Research Use Disclaimer
This product is intended strictly for laboratory research use only. It is not for human use, diagnosis, or treatment. Proper lab safety and handling procedures must be followed. Misuse is prohibited and may be subject to local regulations.
Additional information
| Weight | 1 kg |
|---|---|
| Dimensions | 26 × 23 × 26 cm |
1 review for Sitagliptin and Metformin Hydrochloride Extended 100mg low price supplier
Q1: Is this tablet suitable for human therapeutic use?
No. This product is labeled for laboratory research only, and not approved for clinical use in humans or animals.
Q2: What are common lab uses of this tablet?
It is widely used to study insulin resistance, incretin hormone regulation, and combined therapy modeling for type 2 diabetes.
Q3: Are COA and SDS available?
Yes. Upon order confirmation, COA (Certificate of Analysis) and SDS (Safety Data Sheet) can be provided upon request.
Q4: Do you accept wholesale orders?
Absolutely. We support both bulk purchases for institutions and small-scale retail orders for individual labs.
Q5: Why is this product valuable in diabetes research?
Because the combination of sitagliptin and metformin targets both incretin degradation and hepatic glucose output, it's ideal for multi-mechanism T2DM research in experimental models.
Q6:What is sitagliptin and metformin hydrochloride as extended-release tablets?
Metformin and sitagliptin combination is used to treat high blood sugar levels caused by type 2 diabetes. Metformin reduces the absorption of sugar from the stomach, reduces the release of stored sugar from the liver.For Research Use Only
Related products
Epalrestat Tablets 50mg – For Laboratory Research Use Only
Epalrestat Tablets provide 50mg of active compound per tablet. Manufactured by Hebei Ruisen Pharmaceutical Co., Ltd. Approved under H20253680. Intended strictly for laboratory research use only. Supports both bulk and individual orders.?For wholesale prices, other specifications and uses, please consult our staff?
$2.00Pioglitazone Hydrochloride Tablets (Aiting) 15mg – For Laboratory Research Use Only
Pioglitazone Hydrochloride Tablets (Aiting) contain 15mg of active compound per tablet. Supplied as 14 tablets (2 blister packs). Manufactured by Beijing Taiyang Pharmaceutical under NMPA approval H20040267. Suitable for lab research in glucose metabolism and insulin signaling.?For wholesale prices, other specifications and uses, please consult our staff?
$1.20Empagliflozin Tablets 10mg (Koltangen) – For Research Use Only
Empagliflozin Tablets (10mg) for research use only. Used in experimental studies on SGLT2 inhibition, glucose excretion, and type 2 diabetes models. Manufactured by Sichuan Kelun Pharmaceutical Co., Ltd.?For wholesale prices, other specifications and uses, please consult our staff?
$1.00Finerenone Tablets
Finerenone 10mg tablets (28 per box), branded as Kerendia by Bayer AG, are approved for research into chronic kidney disease and cardiovascular protection in Type2 diabetes. NMPA approved (HJ20220057) and globally recognized.
For laboratory research use only – not for human consumption or therapeutic use. $2.00
premi –
Thanks